Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Episodes
Mentioned books
Jun 20, 2025 • 22min
ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04
Join Dr. Erika Hamilton, a medical oncologist from the Sarah Cannon Research Institute, as she shares her expertise on groundbreaking breast cancer research from ASCO 2025. The discussion dives into the INAVO120 trial's survival benefits for specific patient groups, the promising results of SERENA-6 using ctDNA for better therapeutic decisions, and the significant progress shown in DESTINY-Breast09 and ASCENT-04 for treating advanced HER2-positive and triple-negative breast cancers. Explore the future of cancer treatment with these practice-changing insights!
Jun 14, 2025 • 24min
ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Cathy Eng, a renowned GI medical oncologist from the Vanderbilt Ingram Cancer Center, to discuss the most impactful updates from the ASCO 2025 annual meeting, specifically focusing on gastrointestinal (GI) malignancies.
Join us as we dive into five pivotal abstracts that are set to change the landscape of GI cancer treatment:
1. DYNAMIC III: Discover how ctDNA-guided adjuvant chemotherapy in stage 3 colon cancer did not improve outcomes, highlighting questionable role of escalating approach with ctDNA positivity.
2. ATOMIC: Learn about the addition of atezolizumab to FOLFIRI in MSI-H disease stage 3 colon cancer, which improved disease-free survival with a hazard ratio of 0.50.
3. BREAKWATER: Explore how the combination of encorafenib, cetuximab, and FOLFOX has established a new standard of care for BRAF V600E mutant metastatic colorectal cancer, doubling overall survival from 15 months to 30.3 months.
4. MATTERHORN: Understand the use of durvalumab in the perioperative and postoperative setting with the FLOT regimen for resectable gastric and GE junction adenocarcinoma, showing significant improvements in event-free survival.
5. DESTINY Gastric04: Delved into the findings that confirm TDXd as a preferred option in the second line and beyond for HER2 positive metastatic gastric cancer or GE junction adenocarcinoma.
YouTube: https://youtu.be/hllyI5S2Dqg
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don’t forget to subscribe for more episodes on treatment algorithms, FDA approvals, and conference highlights.
Jun 7, 2025 • 26min
ASCO 2025 Lung Cancer Highlights: CheckMate 816, ToD, NeoADAURA, IMforte, DeLLphi 304
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu from Georgetown Lombardi Comprehensive Cancer Center to discuss the latest and most impactful findings from the ASCO 2025 meeting, focusing on lung cancer.
Join us as we dive into five key studies that could change clinical practice:
1. CheckMate 816: Discover the significant overall survival benefits of neoadjuvant chemotherapy combined with nivolumab in resectable non-small cell lung cancer.
2. Timing of Immunotherapy: Explore a groundbreaking study that reveals how the timing of immunotherapy infusions can dramatically affect patient outcomes.
3. NeoADAURA Trial: Learn about the use of osimertinib in the neoadjuvant setting for EGFR-mutated lung cancer and how it compares to established adjuvant therapies.
4. IMforte Study: Understand the implications of maintenance therapy in small cell lung cancer and how it can improve overall survival rates.
5. DeLLphi 304: Get insights into the efficacy of tarlatamab as a second-line treatment for small cell lung cancer and its potential to become the new standard of care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Tune in for an engaging discussion filled with expert insights, clinical pearls, and the latest advancements in lung cancer treatment. Don't forget to like, subscribe, and check out our other conference highlights!
#OncologyBrothers #LungCancer #ASCO2025 #CancerResearch #Immunotherapy #EGFR #SmallCellLungCancer #NeoadjuvantTherapy #Podcast
May 26, 2025 • 14min
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.
Join us as we delve into:
• The significance of MSI-high status in colorectal cancer and its prevalence.
• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.
• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.
• Important side effects associated with the combination therapy and how to manage them.
• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.
• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.
YouTube: https://youtu.be/wJRlECiY2VA
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!
#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
May 21, 2025 • 24min
Managing Toxicities of EGFR Inhibitors: Afatinib, Amivantamab-Lazertinib, Osimertinib
Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center, dives into the world of EGFR inhibitors like Afatinib and Osimertinib. He discusses the evolution of these therapies and highlights common side effects, including skin toxicity and diarrhea. Strategies for managing these toxicities are shared to improve patient quality of life. Insights from recent studies reveal new combinations that enhance treatment effects, while emphasizing the importance of proactive care to optimize outcomes.
May 19, 2025 • 23min
How to treat Small Cell Lung Cancer in 2025
Dr. Ticiana Leal, a thoracic medical oncologist at the Winship Cancer Institute of Emory University, shares insights on small cell lung cancer treatment. She discusses recent breakthroughs like durvalumab approvals and immunotherapy options, emphasizing the importance of clinical trials. The conversation dives into the effectiveness of growth factors, yet points out their underutilization. Innovations in treatment methods, including the potential of novel therapies like Tarlatamab, are also highlighted, showcasing the dynamic future of lung cancer care.
May 15, 2025 • 22min
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
This discussion features Dr. Susan Scott, a thoracic medical oncologist from Johns Hopkins, who specializes in lung cancer treatment. She delves into the latest options for metastatic non-small cell lung cancer, such as osimertinib and various chemotherapy combinations. The significance of comprehensive NGS testing and adjusting treatment plans based on patient responses is emphasized. Scott also provides insights into managing side effects and the role of immunotherapy in treatment, highlighting the importance of patient choices in their care.
May 12, 2025 • 21min
How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations
Dr. Mark Awad, a thoracic medical oncologist from Memorial Sloan Kettering, joins the discussion on treating metastatic non-small cell lung cancer (NSCLC) without actionable mutations. He highlights the significance of next-generation sequencing and PD-L1 levels in treatment decisions. Insights into current options for patients with varying PD-L1 scores are shared, detailing single-agent immunotherapy and chemotherapy combinations. Dr. Awad also delves into second-line treatment options and the evolving landscape of targeted therapies, stressing the need for ongoing clinical trials.
May 8, 2025 • 15min
Managing Side Effects of HER2 Targeted Therapy - Zanidatamab & Trastuzumab deruxtecan (T-DXd)
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab.
The discussion covered:
• Overview of the treatment landscape for biliary tract cancer
• Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue
• Management strategies for adverse events, including dose reductions and supportive care
• Insights on Zanidatamab, its side effects, and infusion-related reactions
• The importance of biomarker testing and patient-centered care in treatment decisions
Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
May 5, 2025 • 22min
Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer
Dr. Thomas Powles, a GU medical oncologist from Barthes Cancer Institute and lead author of the NIAGARA trial, discusses the groundbreaking FDA approval of Durvalumab for muscle-invasive bladder cancer. The conversation delves into the trial's design, showcasing its promising survival rates compared to traditional treatments. Dr. Powles emphasizes the importance of immunotherapy in perioperative settings and the role of ctDNA in tailoring treatment strategies. Listeners gain insights into managing side effects and the evolving landscape of cancer care.
